Tetrandrine Tablets Used in the Treatment of COVID-19

• Status: Enrolling by invitation
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is expected to treat patients with mild and severe neo-coronary pneumonia through standard treatment regimens in combination with tetrandrine tablets, thereby reducing the clinical progress of some patients, improving prognosis, reducing the incidence of pulmonary fibrosis during rehabilitation, and improving patients' quality of life.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henan Provincial People's Hospital
• Treatments: Tetrandrine

Criteria

Inclusion Criteria:

• Patients with mild and severe cases who have been diagnosed with new coronavirus pneumonia according to the "Pneumonitis Diagnosis and Treatment -

• Plan for New Coronavirus Infection"

• Age 18 to 75 years;

• Sign the informed consent voluntarily.

Exclusion Criteria:

• With active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma, bronchiectasis, pulmonary embolism, patients with chronic respiratory failure or other severe respiratory disease;

• According to the "pneumonia diagnosis and treatment program for new coronavirus infection" (trial version 6), critically ill patients

• With severe patients with disease of heart head blood-vessel, malignant arrhythmia, unstable angina, acute myocardial infarction and death, cardiac function level 3 and above, stroke, cerebral hemorrhage, etc.);

• With severe liver and kidney diseases (severe liver disease refers to cirrhosis, portal hypertension and varices bleeding, severe kidney disease including dialysis, kidney transplantation);

• Pregnant and lactating women;

• Severe cognitive and mental disorders;

• Clinical investigators who were participating in other interventions within 1 month prior to inclusion